We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00681837
First Posted: May 21, 2008
Last Update Posted: November 18, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management

Condition
Gastroesophageal Reflux

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • assess prevalence of gastrooesophageal reflux during childhood and teenage years in France, particularly 0-1 year-old prevalence and 1-11 year-old prevalence [ Time Frame: At the end of the study ]

Secondary Outcome Measures:
  • describe patients'symptoms and gastrooesophageal reflux management [ Time Frame: At the end of the study ]

Estimated Enrollment: 2500
Study Start Date: May 2008
Study Completion Date: September 2008
Groups/Cohorts
1
children from 0 to 17 years old

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
children recruited by both GPs and paediatricians
Criteria

Inclusion Criteria:

  • children from 0 to 17years old seen in consultation

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00681837


  Show 25 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Frédéric GOTTRAND CHRU Lille - France
Principal Investigator: Geneviève BONNELYE TNS Healthcare 92120 Montrouge - France
  More Information

Responsible Party: Paula Fernstrom, AstraZeneca
ClinicalTrials.gov Identifier: NCT00681837     History of Changes
Other Study ID Numbers: NIS-GFR-DUM-2008/1
First Submitted: May 19, 2008
First Posted: May 21, 2008
Last Update Posted: November 18, 2008
Last Verified: November 2008

Keywords provided by AstraZeneca:
gastroesophageal reflux
prevalence
childhood
France

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases